Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dr. Reddy's Laboratories Ltd (RDY)
NYSE:RDY
RESEARCH TOOLSreports
Holding RDY?
Track your performance easily
Earnings Data
Report Date
Jan 23, 2025TBA Not Confirmed
Period Ending
2025 (Q4)Consensus EPS Forecast
0.21Last Year’s EPS
0.19Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 26, 2018
|% Change Since: -8.48%
|Next Earnings Date:Jul 26, 2018
Earnings Call Sentiment|Neutral
The earnings call highlighted strong financial performance with record revenue and EBITDA, significant growth in the European market, progress in biosimilars, and sustainability accolades. However, there were challenges in the U.S. generics market, regulatory issues in Hyderabad, and a sequential decline in the India business.Company Guidance
In the Q3 FY '25 earnings call for Dr. Reddy's Laboratories, the company reported a robust financial performance, marked by a 16% year-on-year revenue growth to INR 8,359 crores (USD 977 million) and a 27.5% EBITDA margin. The newly acquired Nicotine Replacement Therapy (NRT) business contributed INR 605 crores to the revenue. Excluding NRT, the underlying growth was 7.5% year-on-year. The gross profit margin stood at 59%, with significant contributions from Global Generics and PSAI segments at 61.3% and 28.6%, respectively. The SG&A expenses rose by 19% year-over-year to INR 2,412 crores, driven by the NRT acquisition and increased logistics costs. The R&D expenditure was INR 666 crores, representing 8% of sales, with a focus on complex generics and biosimilars. The company anticipates maintaining an R&D spend of 8.5% to 9% of sales for the full fiscal year. Profit before tax was INR 1,874 crores, with an effective tax rate of 25.1%. The company reported an EPS of INR 16.94, reflecting a 13% quarter-on-quarter growth in profit after tax.Record Quarterly Revenue and EBITDA
Dr. Reddy's Laboratories achieved its highest ever quarterly revenue and EBITDA in Q3 FY '25, driven by a 16% year-on-year revenue growth to INR 8,359 crores (USD 977 million) and the inclusion of the Nicotine Replacement Therapy business.
Strong Growth in Europe
The European Generics business, including NRT, recorded USD 134 million in revenue, a 142% year-over-year increase. Excluding NRT, the growth was 22% YoY.
Significant Progress in Biosimilars
Dr. Reddy's secured marketing authorization for rituximab in the U.K. and filed denosumab in both the U.S. and Europe, marking progress in their biosimilars journey.
Sustainability and ESG Recognition
Dr. Reddy's achieved an ESG score of 79 out of 100, placing them fifth globally among pharma companies in the S&P Global CSA. They continue to be members of the DJSI World Index and have an upgraded MSCI ESG rating of A.
---
RDY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
RDY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Jan 23, 2025 | $15.09 | $14.15 | -6.23% |
| Nov 05, 2024 | $14.80 | $14.61 | -1.28% |
| May 07, 2024 | $14.90 | $14.20 | -4.70% |
| Jan 30, 2024 | $13.94 | $13.81 | -0.93% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Dr. Reddy's Laboratories Ltd (RDY) report earnings?
Dr. Reddy's Laboratories Ltd (RDY) is schdueled to report earning on Jan 23, 2025, TBA Not Confirmed.
What is Dr. Reddy's Laboratories Ltd (RDY) earnings time?
Dr. Reddy's Laboratories Ltd (RDY) earnings time is at Jan 23, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RDY EPS forecast?
RDY EPS forecast for the fiscal quarter 2025 (Q4) is 0.21.
---